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Tumors are composed of abnormally transformed cell types and tissues that differ from 
normal tissues in their genetic and epigenetic makeup, metabolism, and immunology. 
Molecular compounds that modulate the immune response against neoplasms offer 
promising new strategies to combat cancer. Inhibitors targeting the indoleamine-2,3- 
dioxygenase 1 enzyme (IDO1) represent one of the most potent therapeutic opportu-
nities to inhibit tumor growth. Herein, we assess the biochemical role of IDO1 in tumor 
metabolism and immune surveillance, and review current diagnostic and therapeutic 
approaches that are intended to increase the effectiveness of immunotherapies against 
highly aggressive and difficult-to-treat IDO-expressing cancers.
Keywords: indoleamine-2,3-dioxygenase, gene expression, metabolism, immunotherapy, immune surveillance, 
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inTRODUCTiOn
Biochemistry and Regulation of indoleamine-2,3-Dioxygenase 1 
(iDO1) Activity
Indolamine-2,3-dioxygenase 1 is a cytosolic enzyme with a heme (Fe2+) prosthetic group that cata-
lyzes the first and rate-limiting step of tryptophan (Trp) catabolism (Figure 1A). IDO1 converts the 
essential amino acid Trp to kynurenine (Kyn) by cleaving the 2,3-double bond of the indole ring while 
a molecular oxygen (O2) merges into the unsealed molecule. The product is N-formylkynurenine 
that becomes rapidly and spontaneously transformed into Kyn (1). In the next steps, Kyn is further 
converted to other active metabolites, such as hydroxykynurenine, anthranilic acid, kynurenic acid, 
3-hydroxyanthranilic acid, quinolinic acid, and picolinic acid (Figure 1A). The two end-products of 
the pathway are NAD+ and ATP that both fuel cellular metabolism (2).
In humans, IDO1 has an evolutionary paralog (indolamine-2,3-dioxygenase 2; IDO2) and a 
functional ortholog (tryptophan-2,3-dioxygenase; TDO) that catalyze the same biochemical reaction; 
however, IDO2 and TDO show high tissue specificity and much lower expression level than IDO1 that 
significantly restrict their activity (2, 4). TDO is transcribed only in the liver1 [protein-level expression is 
not established (5)] and its major function is to control the free Trp concentration of the blood (4). IDO2 
mRNA is expressed at low levels in the placenta and liver (protein expression is not known2), while IDO1 
shows a high protein expression in the peripheral lymph organs (lymph nodes, spleen and tonsils3).
1 https://www.proteinatlas.org/ENSG00000151790-TDO2/tissue.
2 https://www.proteinatlas.org/ENSG00000188676-IDO2/tissue.
3 https://www.proteinatlas.org/ENSG00000131203-IDO1/tissue.
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FigURe 1 | The biochemical function and regulation of indolamine-2,3-dioxygenase 1 (IDO1). (A) The kynurenine (Kyn) pathway of tryptophan (Trp) catabolism. 
l-Trp is metabolized in three separate biochemical pathways (indicated by arrows). In the Kyn pathway, IDO1/IDO2 and tryptophan-2,3-dioxygenase (TDO) catalyze 
the first and rate-limiting step of Trp degradation that gives rise to N-formylkynurenine. N-formylkynurenine is then transformed into l-Kyn and formic acid by 
kynurenine formamidase. l-Kyn is converted to anthranilic acid by kynureninase or l-hydroxykynurenine by kynurenine hydroxylase. Non-specific hydroxylation of 
anthranilic acid results in l-hydroxykynurenine. Kynureninase converts l-hydroxykynurenine to 3-hydroxyanthranilic acid that is further metabolized by 
hydroxyanthranilate dioxygenase to aminocarboxymuconic semialdehyde. The semialdehyde spontaneously forms quinolinic acid that is a precursor of NAD+ 
synthesis, or a decarboxylase enzyme converts it to aminomuconic semialdehyde. Aminomuconic semialdehyde is then converted to picolinic acid or glutaryl-CoA 
that is metabolized in the tricarbonic acid cycle and terminal oxidation. Metabolites that are highlighted in red have been directly implicated in immunosuppressive 
mechanisms and cancer development. (B) The structure of the IDO1 gene. IDO1 is located on chromosome 8 [39771328–39786309 forward (+) strand; 14,982 
base pairs] comprising 10 exonic region (red bars). The promoter region (green section upstream the transcription start site) contains several transcription 
factor-binding sites that have been identified by ChIP sequencing. ChIP peaks were collected from the GTRD database of transcription binding sites (3). Only normal 
(non-transformed) cell types were considered. (C) The role of IDO1 in cancer immunoediting. In the first phase of immunoediting (“elimination”), sporadically arising 
transformed cells are destroyed by the innate and adaptive immune systems. Activated B cells produce tumor reactive antibodies to eradicate most transformed 
cells. Natural killer (NK) cells and effector T cells release inflammatory cytokines, such as IFN-γ, which activate dendritic cells (DCs) that secrete low levels of IDO1. 
IDO1 depletes the essential amino acid Trp from the tumor microenvironment that inhibits tumor growth. In the “equilibrium” phase, surviving tumor cells are still 
controlled by the immune system; however, they rapidly accumulate mutations. When the immune system can no longer block the abnormal and autonomous 
growth of “edited” cells, the tumor becomes clinically manifested (“escape”). The escape phase is associated with high IDO1 level that is primarily produced by 
tumor cells and tolerogenic immune cells [e.g., tolerogenic DCs, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs)]. Trp depletion 
and Kyn accumulation lead to immunosuppression and tolerogenicity by inhibiting effector T cell and NK cell functions and stimulating regulatory T cells. IDO1 also 
promotes the expansion and activation of MDSCs and induces polarization of macrophages to a tolerogenic phenotype. Increased Kyn levels activate the aryl 
hydrocarbon receptor (AhR) that switch the activity of DCs from immunogenic to tolerogenic. Elevated CTLA4 expression of regulatory T cells results in further 
increase of IDO1 secretion by DCs. IDO1-induced expansion and activation of regulatory T cells, tolerogenic DCs, and MDSCs suppress the activity of antitumor 
effector T cells. Other immunosuppressive agents (e.g., PD-L1/PD-1, CTLA4) also inhibit effector T cell functions. Oncological immunotherapy aims to reverse 
immunoediting (backward arrow) by inhibiting and activating local immunosuppressive and tumor eradication mechanisms, respectively.
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The activity of IDO1 is mainly regulated at the transcrip-
tional level (Figure 1B). Bona fide transcription factor binding 
sites have been detected by ChIP-seq for a large catalog of 
human transcription factors (3). The identified gene regulatory 
proteins involve (i) NF- κB, which allows IDO1 mRNA expres-
sion regulation through the interferon pathway (6), (ii) the aryl 
hydrocarbon receptor (AhR) that binds to putative dendritic-
cell responsive elements and promotes the l-Kyn-dependent 
induction of IDO1 (7, 8), and (iii) CTCF that mediates IDO1 
expression via long-range chromatin looping interactions 
between the promoter and distal enhancer regions (9).
Superimposed on the transcriptional control of IDO1, specific 
posttranslational mechanisms also operate that affect the activity 
and half-life of the enzyme. For instance, the diffusible messenger 
nitrogen monoxide (NO) reacts with the heme cofactor of IDO1 
generating ferric (Fe3+) heme and nitrate (NO3), which leads to the 
dose-dependent and reversible inhibition of enzymatic activity (10, 
11). It has been also shown that endoge nous NO production acceler-
ates the proteasomal degradation of IDO1 (12). Other antioxidants 
like the anti-inflammatory agent pyrrolidine dithiocarbamate (13) 
restrict the availability of heme and thereby block holoenzyme 
assembly (14). In inflammatory conditions, NO and superoxide 
anions ( )O2−  are simultaneously produced in large amounts, which 
rapidly generate the highly reactive peroxynitrite anion. Peroxynitrite 
inhibits IDO1 via the nitration of critical tyrosine residues (Tyr15, 
Tyr345, and Tyr353), without affecting IDO1 protein level (15, 16).
Hypoxia also leads to reduced IDO1 expression and, therefore, 
reduced Kyn production (17). Low IDO1 activity during the 
hypoxic phase promotes the activation of immune cells (18); 
however, hypoxic conditions also augment the secretion of effec-
tor CD4(+) T-cell cytokines, especially IFN-gamma, which in 
turn upregulates IDO1 mRNA expression (19).
At the protein level, IDO1 is mainly regulated by proteasomal 
degradation in response to immunogenic stimuli. Suppressor of 
cytokine signaling 3 (SOCS3), for instance, binds to IDO1 under 
inflammatory conditions and targets the IDO1/SOCS3 complex 
for polyubiquitination and proteasomal digestion. IDO1 degrada-
tion converts tolerogenic dendritic cells (DCs) into immunogenic 
cells and, therefore, a prerequisite for normal dendritic-cell func-
tion (20). Activated AhR is another component of the ubiquitin/
proteasome system that contributes to the regulatory proteolysis 
of IDO1 and other proteins (8) that affect IDO1’s half-life.
Indoleamine-2,3-dioxygenase 1 contains two phosphorylatable 
tyrosine residues (Y115 and Y253) that modulate its enzymatic 
activity (21). Phosphorylation of any of these resi dues results in 
conformational changes in IDO1 and blocks the catalytic activity of 
IDO1 (22). In addition to the regulation of catalytic activity, these 
motifs act as docking sites for various molecular partners that either 
prolong or shorten IDO1’s half-life and maintain its immunoregu-
latory effects or stimulate inflammatory responses, respectively (8). 
For example, IL-6 triggers the phosphorylation of the Y253 residue 
of IDO1 that recruits the ECS (Elongin-Cullin-SOCS) E3 ligase 
complex, targeting IDO/SOCS3 for proteasomal degradation (23). 
On the contrary, phosphorylation of the Y115 residue allows the 
binding of SH2 domain tyrosine phosphatases SHP1 and SHP2, 
while SOCS3 becomes excluded. Hence, the TGF-β/Fyn/SHP axis 
activates the non-canonical NF-κB pathway that upregulates IDO1 
production. Recently, ligand-bound AhR and Arginase 1 have 
been also shown to promote IDO1 phosphorylation through Src 
kinases, activating the signaling function of IDO1 that leads to de 
novo synthesis of the enzyme via TGF-β production (8, 24, 25).
The Physiological and Pathological 
Function of iDO1
The IDO1 pathway was originally described as an innate 
immune mechanism that defended the host organism against 
infections (26). The immunoprotective role of IDO1 was directly 
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supported by the anti-pathogen effect of Trp metabolites (l-Kyn, 
l-hydroxykynurenine, 3-hydroxyanthranilic acid, quinolinic 
acid, picolinic acid) that prevented the proliferation and spread 
of intracellular pathogens (4, 27). Subsequent studies, however, 
identified tissue macrophages producing high levels of IDO1 
upon IFN-γ stimulation that strongly inhibited the proliferation 
of effector T cells (28). It was also shown that accumulating Trp 
metabolites induced the differentiation of regulatory T cells and 
apoptosis of effector T  cells that gave rise to immunosuppres-
sion (4, 26). l-Kyn is particularly toxic to lymphocytes (2) and 
induces the differentiation of regulatory T cells via AhR binding 
(29). l-hydroxykynurenine aids the suppression of CD4+ T cells 
and promotes the action of regulatory T cells (30). 3-hydroxy-
anthranilic acid modulates the immune functions of monocytes 
and lymphocytes, induces the apoptosis of effector T cells, and 
promotes the proliferation of regulatory T cells. Quinolinic acid 
stimulates the cell cycle of cancer cells and contributes to the 
acquisition of multidrug resistance against chemotherapeutic 
agents (29). Picolinic acid inhibits effector T  cell proliferation 
(31). Later, it has become clear that the balance between the 
immunoprotective and immunosuppressive roles of IDO1 and 
Trp metabolites is tightly controlled by the stoichiometry of 
available local factors (e.g., IL-6, IL-12, CD40, IFN-γ, CTLA4, 
Foxo3a, IL-10, and PD-1) (26, 32). The resultant effect of these 
local activities modulates IDO1 expression and helps maintain 
global immune homeostasis and peripheral immune tolerance.
There are many pathologic diseases that are associated with 
increased IDO1 activity, including atherosclerosis, obesity, auto-
immunity, major infections (e.g., community-acquired pneumo-
nia, tuberculosis, listeriosis, influenza, HBV, HCV, HIV, sepsis), 
rejection of organ transplants, and cancer (2, 27). Originally, 
IDO1 has been considered as an anti-cancer molecule, proposing 
that increased IDO1 activity of antigen-presenting cells depletes 
the essential amino acid Trp from tumor cells and inhibits their 
growth. However, with the discovery of IDO1-mediated immu-
nosuppressive functions, the pro-cancer activity of the enzyme 
has been recognized (33). IDO1 is overexpressed in more than 
50% of tumors (34) that utilize IDO1-associated immunosup-
pressive mechanisms to promote their spread and survival (35). 
In cervical cancer, for instance, IDO1 shows a significantly 
higher mRNA transcription and protein expression level than 
in normal cervix, and also in comparison to other cancers (36). 
The extent of IDO overexpression also depends on the type 
of tumor and risk factors that reach patients in their life. For 
instance, oral squamous cell carcinoma (OSCC) was compared 
in never-smokers and never-drinkers (NSND) with smoker and 
drinker (SD) patients. In NSND patients suffering from OSCC, 
expression of IDO1 was significantly higher than in SDs (37).
Indoleamine-2,3-dioxygenase1 production is elevated upon 
(i) IFN-γ production of effector T  cells (2), (ii) inflammatory 
cytokine production of innate immune cells (6, 38), (iii) IL-10 
and IL-27 stimulation (39), (iv) CTLA4 expression on Treg cells 
causing increased IDO1 secretion by dendritic cells (DCs) (40), 
and (v) TGF-β, IL-10 and adenosine production of Treg and 
other immunosuppressive cells (40–42), (vi) cyclooxygenase-2 
(COX-2) and prostaglandin E2 (PGE2) stimuli that are mediated 
through the PKC, PI3K, and MAPK pathways (several types of 
tumors carry PI3K or MAPK oncogenic mutations leading to 
constitutive IDO1 expression.) (43).
The mechanism of IDO1-elicited immunosuppression is not 
fully understood; however, increased IDO1 and Kyn levels are 
known to inhibit natural killer (NK) cell function (44, 45), prevent 
the activation of effector T cells, stimulate the activation of Treg 
cells (35, 46) and the differentiation of tolerogenic DCs (47), and 
promote the expansion and activation of myeloid-derived sup-
pressor cells (48). Furthermore, Trp depletion inhibits mechanis-
tic target of rapamycin complex 1 that stimulates T cell apoptosis 
and antigen-presenting cell-mediated inflammation (1, 49).
Paradoxically, the adaptive and innate immune systems that 
primarily protect against cancer development drive the formation 
of the highly aggressive and difficult-to-treat IDO1+ tumors. The 
genetic and biochemical characteristics of the emerging tumor 
is established by the process of “immunoediting” that prevents 
and promotes tumor formation at the same time, involving 
three consecutive stages called “elimination,”, “equilibrium,” and 
“escape” (50) (Figure 1C). In the first phase (“elimination”), most 
transformed cells are efficiently recognized and destroyed by 
the action of effector cells as NK and T cells (50). At this stage, 
IDO1 is produced at low levels within the tumor microenviron-
ment and inhibits tumor proliferation (33). In the “equilibrium” 
phase, surviving tumor cells become “edited” by the continuous 
attack of the immune system and accumulate mutations (51). 
In the “escape” phase, IDO1 is produced in large quantities by 
tumor cells and tolerogenic immune cells that are recruited to 
the tumor microenvironment (52, 53). Increased IDO1 activity 
leads to elevated Kyn production that prevents effector T  cell 
(35, 46) and NK cell functions (44, 45). In parallel, IDO1 induces 
the activation and expansion of Treg cells (26), DCs (47), and 
MDCSs (48) that further suppress the function of antitumor 
T cells. These mechanisms collectively establish an immunosup-
pressive tumor microenvironment that supports tumor growth. 
IDO1 positivity is strongly associated with multidrug resistance 
of tumors and inversely correlates with patient survival (54). 
Therefore, timely diagnosis and therapeutic correction of IDO+ 
tumors are of crucial importance to prevent clinical manifestation.
iDO1 in Cancer Diagnostics and Therapy
Indoleamine-2,3-dioxygenase 1 overexpression increases the 
relative concentration of Kyn compared to Trp, hence Kyn/Trp 
ratio can be used as a prognostic clinico-pathological marker 
to monitor cancer invasiveness and progression. Accordingly, 
increased systemic Kyn/Trp ratio and elevated IDO1 activity have 
been associated with poor prognosis and low survival of patients 
diagnosed with cervical cancer and glioblastoma multiforme (55, 
56). For the sensitive detection of Trp metabolites in IDO1+ tumor 
tissues, a wealth of Trp-based radiotracers has been developed 
for positron emission tomography imaging. Radioactive Trp 
analogs as α-[11C]methyl-l-tryptophan (AMT) and l- and d-1-
[18F]fluoroethyl-tryptophan provide useful information about 
response to immunotherapy, but they are also crucial for the pre-
clinical and clinical validation of novel IDO1 inhibitors (57, 58).
Protein expression of IDO1 was found to be high in a num-
ber of tumor samples (36, 56); therefore, IDO1 may be a rel-
evant therapeutic target to abrogate immune suppression (59). 
TABle 1 | Clinical trials of indoleamine-2,3-dioxygenase (IDO) inhibitors in cancer therapy.
Agent Tumor type nCT number Study phase Recruitment  
status
(estimated) primary 
completion date
IDO peptide vaccine •	 Non-small cell lung cancer (NSCLC) NCT01219348 Phase 1 Completed August 2012
•	 Metastatic malignant melanoma NCT02077114 Phase 1 Completed September 2014
NCT01543464 Phase 2 Terminated September 2016
NCT03047928 Phase 1 Not yet recruiting 1 April, 2019
Phase 2
Indoximod (1-methyl-d-tryptophan; 
D-1MT; NSC-721782)
•	 Unspecified adult solid tumors NCT00567931 Phase 1 Completed July 2012
•	 Breast cancer
•	 Lung cancer
•	 Melanoma
•	 Pancreatic cancer
•	 Solid tumors
NCT00739609 Phase 1 Terminated October 2012
•	 Metastatic breast cancer NCT01302821 Withdrawn December 2014
NCT01792050 Phase 2 Active, not recruiting December 2016
•	 Metastatic melanoma NCT02073123 Phase 1 Recruiting December 2016
Phase 2
•	 Glioblastoma multiforme
•	 Glioma
•	 Gliosarcoma
•	 Malignant brain tumor
NCT02052648 Phase 1 Recruiting December 2016
Phase 2
NCT02502708 Phase 1 Recruiting July 2017
•	 Non-small cell lung cancer (NSCLC) NCT02460367 Phase 1 Recruiting June 2017
Phase 2
•	 Metastatic pancreatic adenocar cinoma
•	 Metastatic pancreatic cancer
NCT02077881 Phase 1 Recruiting July 2017
Phase 2
•	 Acute myeloid leukemia NCT02835729 Phase 1 Recruiting July 2018
Phase 2
Epacadostat (INCB024360, 
4-amino-1,2,5-oxadizaole-3-
carboximidamide)
•	 Advanced malignancies NCT01195311 Phase 1 Completed May 2013
•	 Myelodysplastic syndromes (MDS) NCT01822691 Phase 2 Completed January 2015
•	 Epithelial ovarian cancer
•	 Fallopian tube cancer
•	 Primary peritoneal cancer
NCT01685255 Phase 2 Terminated 23 October, 2014
NCT02118285 Phase 1 Completed 12 November, 2015
NCT02042430 Active, not recruiting 31 March, 2016
NCT01982487 Phase 1 Withdrawn September 2017 
Phase 2
NCT02166905 Phase 1 Recruiting 12 February, 2018
Phase 2
NCT02785250 Phase 1 Recruiting May 2018
NCT02575807 Phase 1 Recruiting December 2018
Phase 2
•	 Mucosal melanoma
•	 Skin melanoma
•	 Uveal melanoma
NCT01961115 Phase 2 Active, not recruiting 31 October, 2016
NCT01604889 Phase 1 Terminated 27 December, 2016
Phase 2
•	 Gastrointestinal stromal tumors NCT03291054 Phase 2 Not yet recruiting September 2019
•	 Recurrent/metastatic endometrial carcinoma NCT03310567 Phase 2 Not yet recruiting 30 January, 2020
•	 Squamous cell carcinoma of the head and neck NCT03325465 Phase 2 Not yet recruiting June 2020
•	 Advanced solid tumors NCT02559492 Phase 1 Active, not recruiting December 2017
NCT03085914 Phase 1 Recruiting April 2021
Phase 2
NCT02959437 Phase 1 Recruiting September 2021
Phase 2
•	 Metastatic pancreatic adenocarcinoma NCT03006302 Phase 2 Not yet recruiting February 2021
•	 Metastatic non-small cell lung cancer (NSCLC) NCT03322540 Phase 3 Not yet recruiting 17 June, 2022
NCT03322566 Phase 3 Not yet recruiting 26 October, 2022
•	 Renal cell carcinoma NCT03260894 Phase 3 Not yet recruiting May 2023
(Continued )
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Agent Tumor type nCT number Study phase Recruitment  
status
(estimated) primary 
completion date
GDC-0919 •	 Advanced solid tumors NCT02048709 Phase 1 Completed February 2016
HTI-1090 (SHR9146) •	 Advanced solid tumors NCT03208959 Phase 1 Not yet recruiting 1 April, 2018
PF-06840003 •	 Oligodendroglioma
•	 Astrocytoma
•	 Malignant glioma
NCT02764151 Phase 1 Recruiting 30 April, 2018
NLG802 •	 Advanced solid tumors NCT03164603 Phase 1 Recruiting May 2018
BMS-986205 •	 Advanced cancer NCT03335540 Phase 1 Not yet recruiting 14 March, 2021
Clinical trials were identified on the website: https://clinicaltrials.gov/ct2/results?cond=&term=IDO&cntry1=&state1=&recrs= as of 9 November, 2017.
TABle 1 | Continued
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Currently, several IDO inhibitors undergo clinical evalua-
tion (60) and many of them are now in Phase II clinical trials 
(Table  1). Most inhibitors were designed to block the Kyn 
pathway (e.g., epacadostat, indoximod, GDC-0919, and an 
IDO1 peptide-based vaccine; Figure 1A) that suspends immu-
nosuppression (1). Some of the tested compounds are used 
alone, or in combination with immunotherapy (CTLA4, PD-1 
blockade), chemotherapy, adoptive transfer, COX-2 inhibitors 
(e.g., celecoxib), membrane-associated PGE2 synthase inhibi-
tors (e.g., MF63), PGE2 receptor (EP4) competitive antagonists 
(e.g., GW627368X), and PI3K inhibitors (43, 59). The latter 
combinative therapies are intended to improve the inhibition of 
local immunosuppression around tumor tissues and to enhance 
tumor eradication (61).
Epacadostat (INCB024360) and indoximod (NLG8189 or 
1-methyl-d-tryptophan) are the most common IDO inhibitors 
that are well tolerated and show obvious beneficial effects in 
cancer therapies; however, both have some major side effects. 
Epacadostat showed grade 3 and 4 adverse effects in patients 
with advanced malignancies, most frequently abdominal pain, 
hypokalemia, fatigue, and some minor effects involving nausea, 
decreased appetite, vomiting, constipation, diarrhea, dyspnea, 
back pain, and cough (62). Indoximod treatment also showed 
some major toxicities in a dose-escalation study, involving grade 
1 fatigue and grade 2 hypophysitis (63). In combination with the 
microtubular poison docetaxel, the most common adverse effects 
of indoximod were fatigue, anemia, hyperglycemia, infection, 
and nausea (62, 63).
Combination of IFN-γ treatment with IDO1 inhibitors is a 
promising new cancer immunotherapeutic strategy that effec-
tively enhances antitumor immunity and eliminates TRCs 
(i.e., stem cell-like cancer cells that are self-renewing, highly 
tumorigenic, and can repopulate tumors). In clinical practice, 
administration of IFN-γ with IDO1 inhibitors is the only onco-
lytic therapy that significantly disrupts TRCs. IFN-γ induces 
the entry of TRCs into dormancy, while IDO1 inhibitor-elicited 
immunosuppression allows effector T cells and NK cells to attack 
dormant TRCs (64). Monotherapies with IDO inhibitors or other 
combinative treatments usually terminate with failure because of 
immune evasion of TRCs, which leads to metastasis formation, 
tumor recurrence and multidrug resistance (64).
Mutational load/neoantigen-burden, basal level of tumor infil-
trating T cells (TILs), differential expression of immune-checkpoint 
genes within the tumor tissue are important biomarkers that help 
predict the tumor’s predisposition toward immune-checkpoint 
inhibitors (ICIs) targeting IDO1, CTLA4, or PD-1 and increase 
the clinical success of immunotherapies. Most ICI-responsive 
cancers (e.g., lung and bladder cancers, melanoma) were associ-
ated with intrinsically high TIL numbers and high mutational 
load/neoantigen-burden, while other cancers (e.g., glioblastoma) 
were predicted to be ICI-resistant based on their biomarker 
profiles (37, 65).
Beyond the application of biomarkers and chemical inhibi-
tors, IDO1 can be genetically targeted by genome editing tools 
that offer new therapeutic opportunities for cancer patients. In 
animal studies, genetic inhibition of IDO1 expression reactivated 
the antitumor immune response against IDO+ cancer cells and 
inhibited tumor growth (63). The shIDO-ST treatment, for 
instance, is based on a Salmonella typhimurium (ST) vector 
that codes for a small hairpin RNA targeting IDO1 (shIDO) 
(66). Intravenously injected shIDO-ST accumulated in the 
tumor tissues of mice, causing IDO1 silencing and concomitant 
infiltration and activation of polymorphonuclear neutrophil 
granulocytes (PMNs). PMNs produced reactive oxygen species 
that established a highly toxic microenvironment for tumor cell 
growth (67). A recent genomic sequencing study that combined 
large-scale tumor exome analysis with MHC I class prediction 
revealed a strong positive correlation between IDO1 expression, 
mutational burden, and neoantigen load in cervical cancers (36). 
The above studies collectively identify IDO1 as an attractive 
target to increase the effectiveness of cancer immunotherapies.
Conclusion and Outlook
The mechanism of “cancer immunoediting” is the direct con-
sequence of a T  cell-dependent immunoselection process that 
drives the formation of IDO1+ tumors. The action of a competent 
immune system is, therefore, determinative for the acquisition 
of cancer immunogenicity. Important posttranslational control 
mechanisms affect the activity and half-life of IDO1 (e.g., NO, 
hypoxia, proteasomal degradation, phosphorylation) that should 
be considered in terms of cancer therapy. For instance, IDO1 
inhibitors could be administered as co-therapeutic agents in the 
presence of redox regulators, IFN-γ, or anti-IL-6. Combining 
IDO1 drugs with the inhibition of specific transcription fac-
tors regulating IDO1 activity (e.g., AhR) may also improve the 
effectiveness and specificity of chemotherapies. Current genome 
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